Lexicon Pharmaceuticals
LXRX
136 hedge funds and large institutions have $505M invested in Lexicon Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 41 increasing their positions, 26 reducing their positions, and 15 closing their positions.
1,280% more call options, than puts
Call options by funds: $3.34M | Put options by funds: $242K
107% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 15
68% more capital invested
Capital invested by funds: $299M → $505M (+$205M)
58% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 26
9% more funds holding
Funds holding: 125 → 136 (+11)
4.66% more ownership
Funds ownership: 71.66% → 76.33% (+4.7%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| 1 |
AG
Artal Group
Luxembourg
|
+$27M |
| 2 |
SC
Sessa Capital
New York
|
+$21.7M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$11M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$10.5M |
| 5 |
SL
Siren LLC
Greenwich,
Connecticut
|
+$7.83M |
Top Sellers
LXRX Hedge Fund Activity: Q1 2026 in Review
136 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q1 2026, worth a combined $505M — up 68% from $299M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new LXRX positions and 15 closed out — a net gain of 16 holders — while 41 added to existing stakes and 26 trimmed.
The largest buyer was Artal Group, adding an estimated $27M. The largest seller was Citadel Advisors, cutting an estimated $896K.
- 136 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q1 2026, up from 125 in Q4 2025.
- Funds reported $505M of Lexicon Pharmaceuticals stock for Q1 2026, up 68% quarter-over-quarter.
- 31 funds opened new Lexicon Pharmaceuticals positions in Q1 2026 and 15 closed out, a net change of +16 holders.
- The largest Lexicon Pharmaceuticals buyer in Q1 2026 was Artal Group, an estimated $27M added.
- The largest Lexicon Pharmaceuticals seller in Q1 2026 was Citadel Advisors, an estimated $896K sold.
Based on aggregated 13F filings for Q1 2026.